Climb Bio's Upcoming Data Updates on CLYM116, Budoprutug to Be 'More Incremental,' RBC Says

MT Newswires Live10-13

Climb Bio's (CLYM) upcoming data readouts for its CLYM116 and budoprutug investigational therapies are likely to be more incremental and should help de-risk both programs, RBC Capital Markets said in a Tuesday note.

The data updates are expected to be presented at an event in October and RBC said updates on CLYM116 in patients with IgA nephropathy will include "more mature data" while data from Climb Bio's Chinese partner, Mabworks, will cover CLYM116 in healthy volunteers.

Meanwhile, new data on budoprutug is expected to be consistent with previous findings and should back the therapy's opportunity in primary membranous nephropathy, the investment firm added.

The two investigational therapies present a total out-year sales potential of about $1.6 billion, RBC noted.

RBC has an outperform rating on Climb Bio, with a $23 price target.

Price: 10.59, Change: -0.24, Percent Change: -2.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment